Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357450 | 0.86 | EPAS1 (0.48) | EPAS1GRM5CYP3A4PTGER4PTGER2 | |
| SCHEMBL5357850 | 0.85 | EPAS1 (0.62) | EPAS1PTGER4TDP1ABL1PTGER2 | |
| SCHEMBL4449413 | 0.83 | PTGER4 (0.57) | EPAS1PTGER4TDP1ABL1PTGER2 | |
| SCHEMBL4446808 | 0.82 | PTGER4 (0.59) | EPAS1PTGER4TDP1ABL1PTGER2 | |
| SCHEMBL5362660 | 0.82 | PTGER4 (0.65) | PTGER4PTGER2 | |
| SCHEMBL3986819 | 0.81 | INPPL1 (0.43) | GRM5CYP3A4PTGER4ABL1MRGPRX4 | |
| SCHEMBL5357436 | 0.79 | TDP1 (0.53) | EPAS1PTGER4TDP1ABL1PTGER2 | |
| SCHEMBL5367633 | 0.78 | P2RX3 (0.48) | EPAS1ABL1 | |
| SCHEMBL5360680 | 0.76 | SCN8A (0.51) | EPAS1PTGER4ABL1PTGER2 | |
| SCHEMBL5360636 | 0.76 | SCN8A (0.57) | EPAS1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | EPAS1 1007/4885GRM5 787/4885CYP3A4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.